NASDAQ · COGT
Healthcare · Biotechnology
$31.02
Down-$0.94 (-2.94%)
Updated Nov 1, 2026, 5:24 AM
SID Score
4.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance · COGT
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
COGT closed at $31.02 after 20 trading sessions, up 0.49% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $31.75 | $32.335 | $30.645 | $31.02 | 2.5M |
| Oct 29, 2026 | $32.86 | $32.86 | $31.68 | $31.96 | 1.52M |
| Oct 28, 2026 | $31.77 | $32.68 | $31.68 | $32.23 | 1.75M |
| Oct 27, 2026 | $31.10 | $32.22 | $30.72 | $32.01 | 1.84M |
| Oct 26, 2026 | $31.41 | $31.545 | $30.52 | $30.91 | 2.21M |
| Oct 23, 2026 | $30.94 | $31.2651 | $30.33 | $31.21 | 1.77M |
| Oct 22, 2026 | $31.07 | $31.91 | $30.86 | $31.31 | 1.18M |
| Oct 21, 2026 | $31.26 | $31.94 | $31.20 | $31.43 | 2.1M |
| Oct 20, 2026 | $30.235 | $31.50 | $30.03 | $31.24 | 2.31M |
| Oct 19, 2026 | $29.66 | $30.23 | $29.51 | $30.01 | 2.54M |
| Oct 16, 2026 | $29.47 | $29.98 | $28.77 | $29.52 | 2.78M |
| Oct 15, 2026 | $28.33 | $29.78 | $28.33 | $29.51 | 3.04M |
| Oct 14, 2026 | $27.93 | $29.05 | $27.735 | $28.15 | 2.3M |
| Oct 13, 2026 | $29.46 | $29.46 | $27.85 | $28.09 | 3M |
| Oct 12, 2026 | $30.81 | $31.07 | $29.63 | $29.78 | 1.86M |
| Oct 9, 2026 | $29.98 | $31.03 | $29.90 | $31.00 | 2.52M |
| Oct 8, 2026 | $29.71 | $30.66 | $28.69 | $30.08 | 3.64M |
| Oct 7, 2026 | $30.05 | $30.43 | $29.88 | $30.14 | 1.26M |
| Oct 6, 2026 | $31.17 | $31.17 | $29.70 | $30.38 | 2.38M |
| Oct 5, 2026 | $31.26 | $31.37 | $29.93 | $30.87 | 1.79M |
The latest Smart Investors Daily articles mentioning COGT.
Company
Market Activity
Research & News
COGT research
Company profile and research snapshot.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | Wedbush | Outperform | — |
| Sep 15, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 17, 2026 | Piper Sandler | Overweight | — |
| Aug 12, 2026 | Guggenheim | Buy | — |
| May 29, 2026 | Wedbush | Outperform | — |
No generated briefing is available yet.
Benzinga · Oct 21, 2026
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 19.53% on an annualized basis producing an average annual return of 30.65%. Currently, Cogent Biosciences has a market capitalization
Yahoo · Oct 20, 2026
Three Regulatory Reviews, No Established Earnings Base Cogent Biosciences, Inc. (NASDAQ:COGT) has moved from proving bezuclastinib’s clinical activity to seeking regulatory approvals across distinct diseases. Its immediate valuation depends on a series of FDA decisions, starting with the November 30 target for a combination treatment in gastrointestinal stromal tumors, rather than on the earnings of […]
Benzinga · Oct 12, 2026
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 14.59% on an annualized basis producing an average annual return of 26.37%. Currently, Cogent Biosciences has a market capitalization
Benzinga · Oct 2, 2026
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 16.44% on an annualized basis producing an average annual return of 28.63%. Currently, Cogent Biosciences has a market capitalization
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning COGT.
